In addition to bringing glucoregulatory benefit,the GLP-1 receptor (GLP-1R) agonist (GLP1-RA) drug class has recently been licensedfor the treatment of obesity, owing to the anorexigenic properties of GLP-1Rengagement in the CNS (Gabery et al., 2020;Secher et al., 2014; Wilding et al., 2021). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.